WHO classification of haematolymphoid tumours
- Biogen Australia Pty Ltd, Investigator-Initiated Research Grant for CAD software in multiple sclerosis: finished Oct 2021 (past)
Updates to Article Attributes
The World Health OrganizatiοnOrganisation (WHO) classification of tumours of haematopoietic and lymphoid tissues is the most widely used pathologic classification system for hematolymphoid neoplasms. The current revision, known as the 45th revised edition, was published in 20162022 and supersedes the 4th edition revised published in 20082016.
TheIMPORTANT: We are in the process of updating this section. For now, the 2016 version forms the basis of the article below 1-3-3.
Classification
Myeloid neoplasms
-
chronic myeloid leukaemia, BCR-ABL1-positive
chronic eosinophilic leukaemia, not otherwise specified
myeloproliferative neoplasm, unclassifiable
-
cutaneous mastocytosis
-
systemic mastocytosis
indolent systemic mastocytosis
smouldering systemic mastocytosis
systemic mastocytosis with an associated haematological neoplasm
aggressive systemic mastocytosis
mast cell leukaemia
mast cell sarcoma
-
myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement
myeloid/lymphoid neoplasms with PDGFRA rearrangement
myeloid/lymphoid neoplasms with PDGFRB rearrangement
myeloid/lymphoid neoplasms with FGFR1 rearrangement
myeloid/lymphoid neoplasms with PCM1-JAK2 (provisional entity)
-
myelodysplastic/myeloproliferative neoplasms
atypical chronic myeloid leukaemia, BCR-ABL1-negative
juvenile myelomonocytic leukaemia
myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
myelodysplastic/myeloproliferative neoplasm, unclassifiable
-
myelodysplastic syndrome with single lineage dysplasia
myelodysplastic syndrome with multilineage dysplasia
-
myelodysplastic syndrome with ring sideroblasts
myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia
myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia
myelodysplastic syndrome with excess blasts
myelodysplastic syndrome with isolated del(5q)
myelodysplastic syndrome, unclassifiable
refractory cytopenia of childhood (provisional entity)
-
myeloid neoplasms with germline predisposition
-
myeloid neoplasms with germline predisposition without a preexisting disorder or organ dysfunction
acute myeloid leukaemia with germline CEBPA mutation
myeloid neoplasms with germline DDX41 mutation
-
myeloid neoplasms with germline predisposition and preexisting platelet disorders
myeloid neoplasms with germline RUNX1 mutation
myeloid neoplasms with germline ANKRD26 mutation
myeloid neoplasms with germline ETV6 mutation
-
myeloid neoplasms with germline predisposition and other organ dysfunction
myeloid neoplasms with germline GATA2 mutation
myeloid neoplasms associated with bone marrow failure syndromes
myeloid neoplasms associated with telomere biology disorders
juvenile myelomonocytic leukaemia associated with neurofibromatosis, Noonan syndrome or Noonan syndrome-like disorders
myeloid neoplasms associated with Down syndrome
-
-
acute myeloid leukaemia and related neoplasms
-
acute myeloid leukaemia with recurrent genetic abnormalities
acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
acute myeloid leukaemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
acute promyelocytic leukaemia with PML-RARA
acute myeloid leukaemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A
acute myeloid leukaemia with t(6;9)(p23;q34.1); DEK-NUP214
acute myeloid leukaemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
acute myeloid leukaemia (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1
acute myeloid leukaemia with BCR-ABL1 (provisional entity)
acute myeloid leukaemia with mutated NPM1
acute myeloid leukaemia with biallelic mutations of CEBPA
acute myeloid leukaemia with mutated RUNX1 (provisional entity)
acute myeloid leukaemia with myelodysplasia-related changes
therapy-related myeloid neoplasms
-
acute myeloid leukaemia, not otherwise specified
acute myeloid leukaemia with minimal differentiation
acute myeloid leukaemia without maturation
acute myeloid leukaemia with maturation
acute myelomonocytic leukaemia
acute monoblastic/monocytic leukaemia
pure erythroid leukaemia
acute megakaryoblastic leukaemia
acute basophilic leukaemia
acute panmyelosis with myelofibrosis
-
myeloid proliferations related to Down syndrome
transient abnormal myelopoiesis
myeloid leukaemia associated with Down syndrome
-
-
acute leukemias of ambiguous lineage
acute undifferentiated leukaemia
mixed phenotype acute leukaemia with t(9;22)(q34.1;q11.2); BCR-ABL1
mixed phenotype acute leukaemia with t(v;11q23.3); KMT2A rearranged
mixed phenotype acute leukaemia, B/myeloid, not otherwise specified
mixed phenotype acute leukaemia, T/myeloid, not otherwise specified
Lymphoid neoplasms
-
-
B-lymphoblastic leukaemia/lymphoma
B-lymphoblastic leukaemia/lymphoma, not otherwise specified
-
B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities
B-lymphoblastic leukaemia/lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
B-lymphoblastic leukaemia/lymphoma with t(v;11q23.3); KMT2A rearranged
B-lymphoblastic leukaemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1
B-lymphoblastic leukaemia/lymphoma with hyperdiploidy
B-lymphoblastic leukaemia/lymphoma with hypodiploidy
B-lymphoblastic leukaemia/lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH
B-lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
B-lymphoblastic leukaemia/lymphoma, BCR-ABL1–like (provisional entity)
B-lymphoblastic leukaemia/lymphoma with iAMP21 (provisional entity)
-
T-lymphoblastic leukaemia/lymphoma
early T-cell precursor lymphoblastic leukaemia (provisional entity)
natural killer (NK) cell lymphoblastic leukaemia/lymphoma (provisional entity)
-
-
mature B-cell neoplasms
monoclonal B-cell lymphocytosis
B-cell prolymphocytic leukaemia
-
splenic B-cell lymphoma/leukaemia, unclassifiable
splenic diffuse red pulp small B-cell lymphoma (provisional entity)
hairy cell leukaemia-variant (provisional entity)
-
heavy-chain diseases
μ heavy-chain disease
γ heavy-chain disease
α heavy-chain disease
-
plasma cell neoplasms
non-IgM monoclonal gammopathy of undetermined significance (IgG/A)
plasma cell myeloma (a.k.a. multiple myeloma)
-
plasma cell myeloma variants
-
monoclonal immunoglobulin deposition diseases
primary amyloidosis
light chain and heavy chain deposition diseases
-
plasma cell neoplasms with associated paraneoplastic syndrome
TEMPI syndrome
extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
-
nodal marginal zone lymphoma
paediatric nodal marginal zone lymphoma (provisional entity)
-
testicular follicular lymphoma
in situ follicular neoplasia
duodenal-type follicular lymphoma
paediatric-type follicular lymphoma
large B-cell lymphoma with IRF4 rearrangement (provisional entity)
primary cutaneous follicle centre lymphoma
-
leukaemic non-nodal mantle cell lymphoma
in situ mantle cell neoplasia
-
diffuse large B-cell lymphoma, not otherwise specified
germinal centre B-cell type
activated B-cell type
T-cell/histiocyte-rich large B-cell lymphoma
primary diffuse large B-cell lymphoma of the central nervous system
primary cutaneous diffuse large B-cell lymphoma, leg type
EBV-positive diffuse large B-cell lymphoma, not otherwise specified
EBV-positive mucocutaneous ulcer (provisional entity)
-
diffuse large B-cell lymphoma associated with chronic inflammation
fibrin-associated diffuse large B-cell lymphoma
intravascular large B-cell lymphoma
-
HHV8-associated lymphoproliferative disorders
multicentric Castleman disease
HHV8-positive diffuse large B-cell lymphoma, not otherwise specified (provisional entity)
HHV8-positive germinotropic lymphoproliferative disorder
Burkitt-like lymphoma with 11q aberration (provisional entity)
-
high-grade B-cell lymphoma
high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
high-grade B-cell lymphoma, not otherwise specified
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma
-
mature T- and NK-cell neoplasms
T-cell large granular lymphocytic leukaemia
chronic lymphoproliferative disorder of NK cells (provisional entity)
aggressive NK-cell leukaemia
-
EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood
systemic EBV-positive T-cell lymphoma of childhood
chronic active EBV infection of T- and NK-cell type, systemic form
hydroa vacciniforme–like lymphoproliferative disorder
severe mosquito bite allergy
adult T-cell leukaemia/lymphoma
extranodal NK-/T-cell lymphoma, nasal type
-
intestinal T-cell lymphoma
enteropathy-associated T-cell lymphoma
monomorphic epitheliotropic intestinal T-cell lymphoma
intestinal T-cell lymphoma, not otherwise specified
indolent T-cell lymphoproliferative disorder of the gastrointestinal tract (provisional entity)
hepatosplenic T-cell lymphoma
subcutaneous panniculitis-like T-cell lymphoma
-
primary cutaneous CD30+ T-cell lymphoproliferative disorders
lymphomatoid papulosis
primary cutaneous anaplastic large cell lymphoma
-
primary cutanoue peripheral T-cell lymphomas, rare subtypes
primary cutaneous γδ T-cell lymphoma
primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (provisional entity)
primary cutaneous acral CD8+ T-cell lymphoma (provisional entity)
primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (provisional entity)
peripheral T-cell lymphoma, not otherwise specified
-
angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin
follicular T-cell lymphoma (provisional entity)
nodal peripheral T-cell lymphoma with T follicular helperphenotype (provisional entity)
breast implant-associated anaplastic large-cell lymphoma (provisional entity)
-
nodular lymphocyte predominant Hodgkin lymphoma
-
classical Hodgkin lymphoma
nodular sclerosis classical Hodgkin lymphoma
lymphocyte-rich classical Hodgkin lymphoma
mixed cellularity classical Hodgkin lymphoma
lymphocyte-depleted classical Hodgkin lymphoma
-
posttransplant lymphoproliferative disorders (PTLD)
plasmacytic hyperplasia PTLD
infectious mononucleosis PTLD
florid follicular hyperplasia PTLD
polymorphic PTLD
-
monomorphic PTLD
monomorphic B-cell PTLD
monomorphic T/NK-cell PTLD
classical Hodgkin lymphoma PTLD
Histiocytic and dendritic cell neoplasms
-
tumours derived from Langerhans cells
indeterminate dendritic cell tumour
interdigitating dendritic cell sarcoma
-
follicular dendritic cell sarcoma
inflammatory pseudotumour-like follicular/fibroblastic dendritic cell sarcoma
fibroblastic reticular cell tumour
disseminated juvenile xanthogranuloma
See also
-<p>The<strong> World Health Organizatiοn (WHO) classification of tumours of haematopoietic and lymphoid tissues</strong> is the most widely used pathologic classification system for hematolymphoid neoplasms. The current revision, known as the 4<sup>th</sup> revised edition, was published in 2016 and supersedes the 4<sup>th </sup>edition published in 2008.</p><p>The 2016 version forms the basis of the article below <sup>1-</sup><sup>3</sup>.</p><h4>Classification</h4><h5>Myeloid neoplasms</h5><ul>- +<p>The<strong> World Health Organisation (WHO) classification of tumours of haematopoietic and lymphoid tissues</strong> is the most widely used pathologic classification system for hematolymphoid neoplasms. The current revision, known as the 5<sup>th</sup> edition, was published in 2022 and supersedes the 4<sup>th </sup>edition revised published in 2016.</p><p><strong>IMPORTANT:</strong> We are in the process of updating this section. For now, the 2016 version forms the basis of the article below <sup>1-3</sup>.</p><h4>Classification</h4><h5>Myeloid neoplasms</h5><ul>
-<a href="/articles/myeloproliferative-neoplasm-1">myeloproliferative neoplasms</a><ul>-<li>-<a href="/articles/chronic-myeloid-leukaemia">chronic myeloid leukaemia</a>, <em>BCR-ABL1</em>-positive</li>-<li><a href="/articles/chronic-neutrophilic-leukemia">chronic neutrophilic leukaemia</a></li>-<li><a href="/articles/polycythaemia-vera">polycythaemia vera</a></li>-<li><a href="/articles/primary-myelofibrosis">primary myelofibrosis</a></li>-<li><a href="/articles/essential-thrombocythemia">essential thrombocythaemia</a></li>-<li>chronic eosinophilic leukaemia, not otherwise specified</li>-<li>myeloproliferative neoplasm, unclassifiable</li>- +<p><a href="/articles/myeloproliferative-neoplasm-1">myeloproliferative neoplasms</a></p>
- +<ul>
- +<li><p><a href="/articles/chronic-myeloid-leukaemia">chronic myeloid leukaemia</a>, <em>BCR-ABL1</em>-positive</p></li>
- +<li><p><a href="/articles/chronic-neutrophilic-leukemia">chronic neutrophilic leukaemia</a></p></li>
- +<li><p><a href="/articles/polycythaemia-vera">polycythaemia vera</a></p></li>
- +<li><p><a href="/articles/primary-myelofibrosis">primary myelofibrosis</a></p></li>
- +<li><p><a href="/articles/essential-thrombocythemia">essential thrombocythaemia</a></p></li>
- +<li><p>chronic eosinophilic leukaemia, not otherwise specified</p></li>
- +<li><p>myeloproliferative neoplasm, unclassifiable</p></li>
-<a href="/articles/mastocytosis">mastocytosis</a><ul>-<li>cutaneous mastocytosis</li>-<li>systemic mastocytosis<ul>-<li>indolent systemic mastocytosis</li>-<li>smouldering systemic mastocytosis</li>-<li>systemic mastocytosis with an associated haematological neoplasm</li>-<li>aggressive systemic mastocytosis</li>-<li>mast cell leukaemia</li>- +<p><a href="/articles/mastocytosis">mastocytosis</a></p>
- +<ul>
- +<li><p>cutaneous mastocytosis</p></li>
- +<li>
- +<p>systemic mastocytosis</p>
- +<ul>
- +<li><p>indolent systemic mastocytosis</p></li>
- +<li><p>smouldering systemic mastocytosis</p></li>
- +<li><p>systemic mastocytosis with an associated haematological neoplasm</p></li>
- +<li><p>aggressive systemic mastocytosis</p></li>
- +<li><p>mast cell leukaemia</p></li>
-<li>mast cell sarcoma</li>- +<li><p>mast cell sarcoma</p></li>
-<li>myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement<ul>-<li>myeloid/lymphoid neoplasms with <em>PDGFRA </em>rearrangement</li>-<li>myeloid/lymphoid neoplasms with <em>PDGFRB </em>rearrangement</li>-<li>myeloid/lymphoid neoplasms with <em>FGFR1 </em>rearrangement</li>-<li>myeloid/lymphoid neoplasms with <em>PCM1-JAK2 </em>(provisional entity)</li>- +<li>
- +<p>myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement</p>
- +<ul>
- +<li><p>myeloid/lymphoid neoplasms with <em>PDGFRA </em>rearrangement</p></li>
- +<li><p>myeloid/lymphoid neoplasms with <em>PDGFRB </em>rearrangement</p></li>
- +<li><p>myeloid/lymphoid neoplasms with <em>FGFR1 </em>rearrangement</p></li>
- +<li><p>myeloid/lymphoid neoplasms with <em>PCM1-JAK2 </em>(provisional entity)</p></li>
-<li>myelodysplastic/myeloproliferative neoplasms<ul>-<li><a href="/articles/chronic-myelomonocytic-leukaemia">chronic myelomonocytic leukaemia</a></li>-<li>atypical chronic myeloid leukaemia, <em>BCR-ABL1</em>-negative</li>-<li>juvenile myelomonocytic leukaemia</li>-<li>myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis</li>-<li>myelodysplastic/myeloproliferative neoplasm, unclassifiable</li>- +<li>
- +<p>myelodysplastic/myeloproliferative neoplasms</p>
- +<ul>
- +<li><p><a href="/articles/chronic-myelomonocytic-leukaemia">chronic myelomonocytic leukaemia</a></p></li>
- +<li><p>atypical chronic myeloid leukaemia, <em>BCR-ABL1</em>-negative</p></li>
- +<li><p>juvenile myelomonocytic leukaemia</p></li>
- +<li><p>myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis</p></li>
- +<li><p>myelodysplastic/myeloproliferative neoplasm, unclassifiable</p></li>
-<a href="/articles/myelodysplastic-syndrome">myelodysplastic syndromes</a><ul>-<li>myelodysplastic syndrome with single lineage dysplasia</li>-<li>myelodysplastic syndrome with multilineage dysplasia</li>-<li>myelodysplastic syndrome with ring sideroblasts<ul>-<li>myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia</li>-<li>myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia</li>- +<p><a href="/articles/myelodysplastic-syndrome">myelodysplastic syndromes</a></p>
- +<ul>
- +<li><p>myelodysplastic syndrome with single lineage dysplasia</p></li>
- +<li><p>myelodysplastic syndrome with multilineage dysplasia</p></li>
- +<li>
- +<p>myelodysplastic syndrome with ring sideroblasts</p>
- +<ul>
- +<li><p>myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia</p></li>
- +<li><p>myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia</p></li>
-<li>myelodysplastic syndrome with excess blasts</li>-<li>myelodysplastic syndrome with isolated del(5q)</li>-<li>myelodysplastic syndrome, unclassifiable</li>-<li>refractory cytopenia of childhood (provisional entity)</li>- +<li><p>myelodysplastic syndrome with excess blasts</p></li>
- +<li><p>myelodysplastic syndrome with isolated del(5q)</p></li>
- +<li><p>myelodysplastic syndrome, unclassifiable</p></li>
- +<li><p>refractory cytopenia of childhood (provisional entity)</p></li>
-<li>myeloid neoplasms with germline predisposition<ul>-<li>myeloid neoplasms with germline predisposition without a preexisting disorder or organ dysfunction<ul>-<li>acute myeloid leukaemia with germline <em>CEBPA </em>mutation</li>-<li>myeloid neoplasms with germline <em>DDX41 </em>mutation</li>- +<li>
- +<p>myeloid neoplasms with germline predisposition</p>
- +<ul>
- +<li>
- +<p>myeloid neoplasms with germline predisposition without a preexisting disorder or organ dysfunction</p>
- +<ul>
- +<li><p>acute myeloid leukaemia with germline <em>CEBPA </em>mutation</p></li>
- +<li><p>myeloid neoplasms with germline <em>DDX41 </em>mutation</p></li>
-<li>myeloid neoplasms with germline predisposition and preexisting platelet disorders<ul>-<li>myeloid neoplasms with germline <em>RUNX1 </em>mutation</li>-<li>myeloid neoplasms with germline <em>ANKRD26 </em>mutation</li>-<li>myeloid neoplasms with germline <em>ETV6 </em>mutation</li>- +<li>
- +<p>myeloid neoplasms with germline predisposition and preexisting platelet disorders</p>
- +<ul>
- +<li><p>myeloid neoplasms with germline <em>RUNX1 </em>mutation</p></li>
- +<li><p>myeloid neoplasms with germline <em>ANKRD26 </em>mutation</p></li>
- +<li><p>myeloid neoplasms with germline <em>ETV6 </em>mutation</p></li>
-<li>myeloid neoplasms with germline predisposition and other organ dysfunction<ul>-<li>myeloid neoplasms with germline <em>GATA2 </em>mutation</li>-<li>myeloid neoplasms associated with bone marrow failure syndromes</li>-<li>myeloid neoplasms associated with telomere biology disorders</li>-<li>juvenile myelomonocytic leukaemia associated with <a href="/articles/neurofibromatosis">neurofibromatosis</a>, <a href="/articles/noonan-syndrome">Noonan syndrome</a> or Noonan syndrome-like disorders</li>-<li>myeloid neoplasms associated with <a href="/articles/down-syndrome">Down syndrome</a>-</li>- +<li>
- +<p>myeloid neoplasms with germline predisposition and other organ dysfunction</p>
- +<ul>
- +<li><p>myeloid neoplasms with germline <em>GATA2 </em>mutation</p></li>
- +<li><p>myeloid neoplasms associated with bone marrow failure syndromes</p></li>
- +<li><p>myeloid neoplasms associated with telomere biology disorders</p></li>
- +<li><p>juvenile myelomonocytic leukaemia associated with <a href="/articles/neurofibromatosis">neurofibromatosis</a>, <a href="/articles/noonan-syndrome">Noonan syndrome</a> or Noonan syndrome-like disorders</p></li>
- +<li><p>myeloid neoplasms associated with <a href="/articles/down-syndrome">Down syndrome</a></p></li>
-<a href="/articles/acute-myeloid-leukaemia">acute myeloid leukaemia</a> and related neoplasms<ul>-<li>acute myeloid leukaemia with recurrent genetic abnormalities<ul>-<li>acute myeloid leukaemia with t(8;21)(q22;q22.1); <em>RUNX1-RUNX1T1</em>-</li>-<li>acute myeloid leukaemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <em>CBFB-MYH11</em>-</li>- +<p><a href="/articles/acute-myeloid-leukaemia">acute myeloid leukaemia</a> and related neoplasms</p>
- +<ul>
-<a href="/articles/acute-promyelocytic-leukemia">acute promyelocytic leukaemia</a> with <em>PML-RARA</em>-</li>-<li>acute myeloid leukaemia with t(9;11)(p21.3;q23.3); <em>MLLT3-KMT2A</em>-</li>-<li>acute myeloid leukaemia with t(6;9)(p23;q34.1); <em>DEK-NUP214</em>-</li>-<li>acute myeloid leukaemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <em>GATA2</em>, <em>MECOM</em>-</li>-<li>acute myeloid leukaemia (megakaryoblastic) with t(1;22)(p13.3;q13.3); <em>RBM15-MKL1</em>-</li>-<li>acute myeloid leukaemia with <em>BCR-ABL1</em> (provisional entity)</li>-<li>acute myeloid leukaemia with mutated <em>NPM1</em>-</li>-<li>acute myeloid leukaemia with biallelic mutations of <em>CEBPA</em>-</li>-<li>acute myeloid leukaemia with mutated <em>RUNX1 </em>(provisional entity)</li>- +<p>acute myeloid leukaemia with recurrent genetic abnormalities</p>
- +<ul>
- +<li><p>acute myeloid leukaemia with t(8;21)(q22;q22.1); <em>RUNX1-RUNX1T1</em></p></li>
- +<li><p>acute myeloid leukaemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <em>CBFB-MYH11</em></p></li>
- +<li><p><a href="/articles/acute-promyelocytic-leukemia">acute promyelocytic leukaemia</a> with <em>PML-RARA</em></p></li>
- +<li><p>acute myeloid leukaemia with t(9;11)(p21.3;q23.3); <em>MLLT3-KMT2A</em></p></li>
- +<li><p>acute myeloid leukaemia with t(6;9)(p23;q34.1); <em>DEK-NUP214</em></p></li>
- +<li><p>acute myeloid leukaemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <em>GATA2</em>, <em>MECOM</em></p></li>
- +<li><p>acute myeloid leukaemia (megakaryoblastic) with t(1;22)(p13.3;q13.3); <em>RBM15-MKL1</em></p></li>
- +<li><p>acute myeloid leukaemia with <em>BCR-ABL1</em> (provisional entity)</p></li>
- +<li><p>acute myeloid leukaemia with mutated <em>NPM1</em></p></li>
- +<li><p>acute myeloid leukaemia with biallelic mutations of <em>CEBPA</em></p></li>
- +<li><p>acute myeloid leukaemia with mutated <em>RUNX1 </em>(provisional entity)</p></li>
-<li>acute myeloid leukaemia with myelodysplasia-related changes</li>-<li>therapy-related myeloid neoplasms</li>-<li>acute myeloid leukaemia, not otherwise specified<ul>-<li>acute myeloid leukaemia with minimal differentiation</li>-<li>acute myeloid leukaemia without maturation</li>-<li>acute myeloid leukaemia with maturation</li>-<li>acute myelomonocytic leukaemia</li>-<li>acute monoblastic/monocytic leukaemia</li>-<li>pure erythroid leukaemia</li>-<li>acute megakaryoblastic leukaemia</li>-<li>acute basophilic leukaemia</li>-<li>acute panmyelosis with myelofibrosis</li>- +<li><p>acute myeloid leukaemia with myelodysplasia-related changes</p></li>
- +<li><p>therapy-related myeloid neoplasms</p></li>
- +<li>
- +<p>acute myeloid leukaemia, not otherwise specified</p>
- +<ul>
- +<li><p>acute myeloid leukaemia with minimal differentiation</p></li>
- +<li><p>acute myeloid leukaemia without maturation</p></li>
- +<li><p>acute myeloid leukaemia with maturation</p></li>
- +<li><p>acute myelomonocytic leukaemia</p></li>
- +<li><p>acute monoblastic/monocytic leukaemia</p></li>
- +<li><p>pure erythroid leukaemia</p></li>
- +<li><p>acute megakaryoblastic leukaemia</p></li>
- +<li><p>acute basophilic leukaemia</p></li>
- +<li><p>acute panmyelosis with myelofibrosis</p></li>
-<li><a href="/articles/myeloid-sarcoma-1">myeloid sarcoma</a></li>-<li>myeloid proliferations related to Down syndrome<ul>-<li>transient abnormal myelopoiesis</li>-<li>myeloid leukaemia associated with Down syndrome</li>- +<li><p><a href="/articles/myeloid-sarcoma-1">myeloid sarcoma</a></p></li>
- +<li>
- +<p>myeloid proliferations related to Down syndrome</p>
- +<ul>
- +<li><p>transient abnormal myelopoiesis</p></li>
- +<li><p>myeloid leukaemia associated with Down syndrome</p></li>
-<li><a href="/articles/blastic-plasmacytoid-dendritic-cell-neoplasm">blastic plasmacytoid dendritic cell neoplasm</a></li>-<li>acute leukemias of ambiguous lineage<ul>-<li>acute undifferentiated leukaemia</li>-<li>mixed phenotype acute leukaemia with t(9;22)(q34.1;q11.2);<em> BCR-ABL1</em>-</li>-<li>mixed phenotype acute leukaemia with t(v;11q23.3); <em>KMT2A </em>rearranged</li>-<li>mixed phenotype acute leukaemia, B/myeloid, not otherwise specified</li>-<li>mixed phenotype acute leukaemia, T/myeloid, not otherwise specified</li>- +<li><p><a href="/articles/blastic-plasmacytoid-dendritic-cell-neoplasm">blastic plasmacytoid dendritic cell neoplasm</a></p></li>
- +<li>
- +<p>acute leukemias of ambiguous lineage</p>
- +<ul>
- +<li><p>acute undifferentiated leukaemia</p></li>
- +<li><p>mixed phenotype acute leukaemia with t(9;22)(q34.1;q11.2);<em> BCR-ABL1</em></p></li>
- +<li><p>mixed phenotype acute leukaemia with t(v;11q23.3); <em>KMT2A </em>rearranged</p></li>
- +<li><p>mixed phenotype acute leukaemia, B/myeloid, not otherwise specified</p></li>
- +<li><p>mixed phenotype acute leukaemia, T/myeloid, not otherwise specified</p></li>
-<a href="/articles/acute-lymphoblastic-leukaemia">precursor lymphoid neoplasms</a><ul>-<li>B-lymphoblastic leukaemia/lymphoma<ul>-<li>B-lymphoblastic leukaemia/lymphoma, not otherwise specified</li>-<li>B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities<ul>-<li>B-lymphoblastic leukaemia/lymphoma with t(9;22)(q34.1;q11.2); <em>BCR-ABL1</em>-</li>-<li>B-lymphoblastic leukaemia/lymphoma with t(v;11q23.3); <em>KMT2A</em> rearranged</li>-<li>B-lymphoblastic leukaemia/lymphoma with t(12;21)(p13.2;q22.1); <em>ETV6-RUNX1</em>-</li>-<li>B-lymphoblastic leukaemia/lymphoma with hyperdiploidy</li>-<li>B-lymphoblastic leukaemia/lymphoma with hypodiploidy</li>-<li>B-lymphoblastic leukaemia/lymphoma with t(5;14)(q31.1;q32.3); <em>IL3-IGH</em>-</li>-<li>B-lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); <em>TCF3-PBX1</em>-</li>-<li>B-lymphoblastic leukaemia/lymphoma, <em>BCR-ABL1</em>–like (provisional entity)</li>-<li>B-lymphoblastic leukaemia/lymphoma with iAMP21 (provisional entity)</li>- +<p><a href="/articles/acute-lymphoblastic-leukaemia">precursor lymphoid neoplasms</a></p>
- +<ul>
- +<li>
- +<p>B-lymphoblastic leukaemia/lymphoma</p>
- +<ul>
- +<li><p>B-lymphoblastic leukaemia/lymphoma, not otherwise specified</p></li>
- +<li>
- +<p>B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities</p>
- +<ul>
- +<li><p>B-lymphoblastic leukaemia/lymphoma with t(9;22)(q34.1;q11.2); <em>BCR-ABL1</em></p></li>
- +<li><p>B-lymphoblastic leukaemia/lymphoma with t(v;11q23.3); <em>KMT2A</em> rearranged</p></li>
- +<li><p>B-lymphoblastic leukaemia/lymphoma with t(12;21)(p13.2;q22.1); <em>ETV6-RUNX1</em></p></li>
- +<li><p>B-lymphoblastic leukaemia/lymphoma with hyperdiploidy</p></li>
- +<li><p>B-lymphoblastic leukaemia/lymphoma with hypodiploidy</p></li>
- +<li><p>B-lymphoblastic leukaemia/lymphoma with t(5;14)(q31.1;q32.3); <em>IL3-IGH</em></p></li>
- +<li><p>B-lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); <em>TCF3-PBX1</em></p></li>
- +<li><p>B-lymphoblastic leukaemia/lymphoma, <em>BCR-ABL1</em>–like (provisional entity)</p></li>
- +<li><p>B-lymphoblastic leukaemia/lymphoma with iAMP21 (provisional entity)</p></li>
-<li>T-lymphoblastic leukaemia/lymphoma<ul><li>early T-cell precursor lymphoblastic leukaemia (provisional entity)</li></ul>- +<li>
- +<p>T-lymphoblastic leukaemia/lymphoma</p>
- +<ul><li><p>early T-cell precursor lymphoblastic leukaemia (provisional entity)</p></li></ul>
-<li>natural killer (NK) cell lymphoblastic leukaemia/lymphoma (provisional entity)</li>- +<li><p>natural killer (NK) cell lymphoblastic leukaemia/lymphoma (provisional entity)</p></li>
-<li>mature B-cell neoplasms<ul>-<a href="/articles/chronic-lymphocytic-leukaemia">chronic lymphocytic leukaemia</a>/<a href="/articles/small-lymphocytic-lymphoma">small lymphocytic lymphoma</a>-</li>-<li>monoclonal B-cell lymphocytosis</li>-<li>B-cell prolymphocytic leukaemia</li>-<li><a href="/articles/splenic-marginal-zone-lymphoma">splenic marginal zone lymphoma</a></li>-<li><a title="Hairy cell leukaemia" href="/articles/hairy-cell-leukaemia">hairy cell leukaemia</a></li>- +<p>mature B-cell neoplasms</p>
- +<ul>
- +<li><p><a href="/articles/chronic-lymphocytic-leukaemia">chronic lymphocytic leukaemia</a>/<a href="/articles/small-lymphocytic-lymphoma">small lymphocytic lymphoma</a></p></li>
- +<li><p>monoclonal B-cell lymphocytosis</p></li>
- +<li><p>B-cell prolymphocytic leukaemia</p></li>
- +<li><p><a href="/articles/splenic-marginal-zone-lymphoma">splenic marginal zone lymphoma</a></p></li>
- +<li><p><a href="/articles/hairy-cell-leukaemia" title="Hairy cell leukaemia">hairy cell leukaemia</a></p></li>
-<a href="/articles/splenic-lymphoma">splenic B-cell lymphoma/leukaemia, unclassifiable</a><ul>-<li>splenic diffuse red pulp small B-cell lymphoma (provisional entity)</li>-<li>hairy cell leukaemia-variant (provisional entity)</li>- +<p><a href="/articles/splenic-lymphoma">splenic B-cell lymphoma/leukaemia, unclassifiable</a></p>
- +<ul>
- +<li><p>splenic diffuse red pulp small B-cell lymphoma (provisional entity)</p></li>
- +<li><p>hairy cell leukaemia-variant (provisional entity)</p></li>
-<a href="/articles/lymphoplasmacytic-lymphoma">lymphoplasmacytic lymphoma</a><ul><li><a href="/articles/waldenstrom-macroglobulinaemia">Waldenström macroglobulinaemia</a></li></ul>- +<p><a href="/articles/lymphoplasmacytic-lymphoma">lymphoplasmacytic lymphoma</a></p>
- +<ul><li><p><a href="/articles/waldenstrom-macroglobulinaemia">Waldenström macroglobulinaemia</a></p></li></ul>
-<li>IgM <a href="/articles/monoclonal-gammopathy-of-undetermined-significance">monoclonal gammopathy of undetermined significance</a>-</li>-<li>heavy-chain diseases<ul>-<li>μ heavy-chain disease</li>-<li>γ heavy-chain disease</li>-<li>α heavy-chain disease</li>- +<li><p>IgM <a href="/articles/monoclonal-gammopathy-of-undetermined-significance">monoclonal gammopathy of undetermined significance</a></p></li>
- +<li>
- +<p>heavy-chain diseases</p>
- +<ul>
- +<li><p>μ heavy-chain disease</p></li>
- +<li><p>γ heavy-chain disease</p></li>
- +<li><p>α heavy-chain disease</p></li>
-<li>plasma cell neoplasms<ul>-<li>non-IgM <a href="/articles/monoclonal-gammopathy-of-undetermined-significance">monoclonal gammopathy of undetermined significance</a> (IgG/A)</li>-<a href="/articles/multiple-myeloma-1">plasma cell myeloma</a> (a.k.a. multiple myeloma)</li>-<li>plasma cell myeloma variants<ul>-<li><a href="/articles/smouldering-multiple-myeloma">smouldering (asymptomatic) plasma cell myeloma</a></li>-<li><a href="/articles/non-secretory-myeloma">non-secretory myeloma</a></li>-<li><a title="Plasma cell leukaemia" href="/articles/plasma-cell-leukaemia">plasma cell leukaemia</a></li>- +<p>plasma cell neoplasms</p>
- +<ul>
- +<li><p>non-IgM <a href="/articles/monoclonal-gammopathy-of-undetermined-significance">monoclonal gammopathy of undetermined significance</a> (IgG/A)</p></li>
- +<li><p><a href="/articles/multiple-myeloma-1">plasma cell myeloma</a> (a.k.a. multiple myeloma)</p></li>
- +<li>
- +<p>plasma cell myeloma variants</p>
- +<ul>
- +<li><p><a href="/articles/smouldering-multiple-myeloma">smouldering (asymptomatic) plasma cell myeloma</a></p></li>
- +<li><p><a href="/articles/non-secretory-myeloma">non-secretory myeloma</a></p></li>
- +<li><p><a href="/articles/plasma-cell-leukaemia" title="Plasma cell leukaemia">plasma cell leukaemia</a></p></li>
-<a href="/articles/plasmacytoma">plasmacytoma</a><ul>-<li><a href="/articles/solitary-bone-plasmacytoma-1">solitary plasmacytoma of bone</a></li>-<li><a href="/articles/extramedullary-plasmacytoma">extraosseous plasmacytoma</a></li>- +<p><a href="/articles/plasmacytoma">plasmacytoma</a></p>
- +<ul>
- +<li><p><a href="/articles/solitary-bone-plasmacytoma-1">solitary plasmacytoma of bone</a></p></li>
- +<li><p><a href="/articles/extramedullary-plasmacytoma">extraosseous plasmacytoma</a></p></li>
-<li>monoclonal immunoglobulin deposition diseases<ul>-<li>primary <a href="/articles/amyloidosis">amyloidosis</a>-</li>-<a href="/articles/light-chain-deposition-disease">light chain</a> and heavy chain deposition diseases</li>- +<p>monoclonal immunoglobulin deposition diseases</p>
- +<ul>
- +<li><p>primary <a href="/articles/amyloidosis">amyloidosis</a></p></li>
- +<li><p><a href="/articles/light-chain-deposition-disease">light chain</a> and heavy chain deposition diseases</p></li>
-<li>plasma cell neoplasms with associated paraneoplastic syndrome<ul>-<li><a href="/articles/poems-syndrome">POEMS syndrome</a></li>-<li>TEMPI syndrome</li>- +<li>
- +<p>plasma cell neoplasms with associated paraneoplastic syndrome</p>
- +<ul>
- +<li><p><a href="/articles/poems-syndrome">POEMS syndrome</a></p></li>
- +<li><p>TEMPI syndrome</p></li>
-<li><a href="/articles/malt-lymphoma">extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)</a></li>-<li>nodal <a href="/articles/marginal-zone-lymphoma">marginal zone lymphoma</a><ul><li>paediatric nodal marginal zone lymphoma (provisional entity)</li></ul>- +<li><p><a href="/articles/malt-lymphoma">extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)</a></p></li>
- +<li>
- +<p>nodal <a href="/articles/marginal-zone-lymphoma">marginal zone lymphoma</a></p>
- +<ul><li><p>paediatric nodal marginal zone lymphoma (provisional entity)</p></li></ul>
-<a href="/articles/follicular-lymphoma">follicular lymphoma</a><ul>-<li>testicular follicular lymphoma</li>-<li>in situ follicular neoplasia</li>-<li>duodenal-type follicular lymphoma</li>- +<p><a href="/articles/follicular-lymphoma">follicular lymphoma</a></p>
- +<ul>
- +<li><p>testicular follicular lymphoma</p></li>
- +<li><p>in situ follicular neoplasia</p></li>
- +<li><p>duodenal-type follicular lymphoma</p></li>
-<li>paediatric-type follicular lymphoma</li>-<li>large B-cell lymphoma with <em>IRF4</em> rearrangement (provisional entity)</li>-<li>primary cutaneous follicle centre lymphoma</li>- +<li><p>paediatric-type follicular lymphoma</p></li>
- +<li><p>large B-cell lymphoma with <em>IRF4</em> rearrangement (provisional entity)</p></li>
- +<li><p>primary cutaneous follicle centre lymphoma</p></li>
-<a href="/articles/mantle-cell-lymphoma">mantle cell lymphoma</a><ul>-<li>leukaemic non-nodal mantle cell lymphoma</li>-<li>in situ mantle cell neoplasia</li>- +<p><a href="/articles/mantle-cell-lymphoma">mantle cell lymphoma</a></p>
- +<ul>
- +<li><p>leukaemic non-nodal mantle cell lymphoma</p></li>
- +<li><p>in situ mantle cell neoplasia</p></li>
-<li>diffuse large B-cell lymphoma, not otherwise specified<ul>-<li>germinal centre B-cell type</li>-<li>activated B-cell type</li>- +<li>
- +<p>diffuse large B-cell lymphoma, not otherwise specified</p>
- +<ul>
- +<li><p>germinal centre B-cell type</p></li>
- +<li><p>activated B-cell type</p></li>
-<li>T-cell/histiocyte-rich large B-cell lymphoma</li>-<li><a href="/articles/primary-cns-lymphoma">primary diffuse large B-cell lymphoma of the central nervous system</a></li>-<li>primary cutaneous diffuse large B-cell lymphoma, leg type</li>-<li><a href="/articles/ebv-positive-diffuse-large-b-cell-lymphoma-nos">EBV-positive diffuse large B-cell lymphoma, not otherwise specified</a></li>-<li>EBV-positive mucocutaneous ulcer (provisional entity)</li>-<li>diffuse large B-cell lymphoma associated with chronic inflammation<ul><li>fibrin-associated diffuse large B-cell lymphoma</li></ul>-</li>-<li><a href="/articles/lymphomatoid-granulomatosis">lymphomatoid granulomatosis</a></li>-<li><a href="/articles/primary-mediastinal-large-b-cell-lymphoma">primary mediastinal (thymic) large B-cell lymphoma</a></li>-<li>intravascular large B-cell lymphoma</li>-<li><a href="/articles/alk-positive-large-b-cell-lymphoma">ALK-positive large B-cell lymphoma</a></li>-<li><a href="/articles/plasmablastic-lymphoma">plasmablastic lymphoma</a></li>-<li><a href="/articles/primary-effusion-lymphoma">primary effusion lymphoma</a></li>-<li>HHV8-associated lymphoproliferative disorders<ul>-<li>multicentric <a href="/articles/castleman-disease">Castleman disease</a>- +<li><p>T-cell/histiocyte-rich large B-cell lymphoma</p></li>
- +<li><p><a href="/articles/lymphomas-of-the-central-nervous-system">primary diffuse large B-cell lymphoma of the central nervous system</a></p></li>
- +<li><p>primary cutaneous diffuse large B-cell lymphoma, leg type</p></li>
- +<li><p><a href="/articles/ebv-positive-diffuse-large-b-cell-lymphoma-nos">EBV-positive diffuse large B-cell lymphoma, not otherwise specified</a></p></li>
- +<li><p>EBV-positive mucocutaneous ulcer (provisional entity)</p></li>
- +<li>
- +<p>diffuse large B-cell lymphoma associated with chronic inflammation</p>
- +<ul><li><p>fibrin-associated diffuse large B-cell lymphoma</p></li></ul>
-<li>HHV8-positive diffuse large B-cell lymphoma, not otherwise specified (provisional entity)</li>-<li>HHV8-positive germinotropic lymphoproliferative disorder</li>- +<li><p><a href="/articles/lymphomatoid-granulomatosis">lymphomatoid granulomatosis</a></p></li>
- +<li><p><a href="/articles/primary-mediastinal-large-b-cell-lymphoma">primary mediastinal (thymic) large B-cell lymphoma</a></p></li>
- +<li><p>intravascular large B-cell lymphoma</p></li>
- +<li><p><a href="/articles/alk-positive-large-b-cell-lymphoma">ALK-positive large B-cell lymphoma</a></p></li>
- +<li><p><a href="/articles/plasmablastic-lymphoma">plasmablastic lymphoma</a></p></li>
- +<li><p><a href="/articles/primary-effusion-lymphoma">primary effusion lymphoma</a></p></li>
- +<li>
- +<p>HHV8-associated lymphoproliferative disorders</p>
- +<ul>
- +<li><p>multicentric <a href="/articles/castleman-disease">Castleman disease</a></p></li>
- +<li><p>HHV8-positive diffuse large B-cell lymphoma, not otherwise specified (provisional entity)</p></li>
- +<li><p>HHV8-positive germinotropic lymphoproliferative disorder</p></li>
-<li><a href="/articles/burkitt-lymphoma">Burkitt lymphoma</a></li>-<li>Burkitt-like lymphoma with 11q aberration (provisional entity)</li>-<li>high-grade B-cell lymphoma<ul>-<li>high-grade B-cell lymphoma with <em>MYC </em>and <em>BCL2 </em>and/or <em>BCL6 </em>rearrangements</li>-<li>high-grade B-cell lymphoma, not otherwise specified</li>- +<li><p><a href="/articles/burkitt-lymphoma">Burkitt lymphoma</a></p></li>
- +<li><p>Burkitt-like lymphoma with 11q aberration (provisional entity)</p></li>
- +<li>
- +<p>high-grade B-cell lymphoma</p>
- +<ul>
- +<li><p>high-grade B-cell lymphoma with <em>MYC </em>and <em>BCL2 </em>and/or <em>BCL6 </em>rearrangements</p></li>
- +<li><p>high-grade B-cell lymphoma, not otherwise specified</p></li>
-<li>B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma</li>- +<li><p>B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma</p></li>
-<li>mature T- and NK-cell neoplasms<ul>-<li><a href="/articles/t-cell-prolymphocytic-leukaemia-1">T-cell prolymphocytic leukaemia</a></li>-<li>T-cell large granular lymphocytic leukaemia</li>-<li>chronic lymphoproliferative disorder of NK cells (provisional entity)</li>-<li>aggressive NK-cell leukaemia</li>-<li>EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood<ul>-<li>systemic EBV-positive T-cell lymphoma of childhood</li>-<li>chronic active EBV infection of T- and NK-cell type, systemic form</li>-<li>hydroa vacciniforme–like lymphoproliferative disorder</li>-<li>severe mosquito bite allergy</li>- +<li>
- +<p>mature T- and NK-cell neoplasms</p>
- +<ul>
- +<li><p><a href="/articles/t-cell-prolymphocytic-leukaemia-1">T-cell prolymphocytic leukaemia</a></p></li>
- +<li><p>T-cell large granular lymphocytic leukaemia</p></li>
- +<li><p>chronic lymphoproliferative disorder of NK cells (provisional entity)</p></li>
- +<li><p>aggressive NK-cell leukaemia</p></li>
- +<li>
- +<p>EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood</p>
- +<ul>
- +<li><p>systemic EBV-positive T-cell lymphoma of childhood</p></li>
- +<li><p>chronic active EBV infection of T- and NK-cell type, systemic form</p></li>
- +<li><p>hydroa vacciniforme–like lymphoproliferative disorder</p></li>
- +<li><p>severe mosquito bite allergy</p></li>
-<li>adult T-cell leukaemia/lymphoma</li>-<li>extranodal NK-/T-cell lymphoma, nasal type</li>-<li>intestinal T-cell lymphoma<ul>-<li>enteropathy-associated T-cell lymphoma</li>-<li>monomorphic epitheliotropic intestinal T-cell lymphoma</li>-<li>intestinal T-cell lymphoma, not otherwise specified</li>-<li>indolent T-cell lymphoproliferative disorder of the gastrointestinal tract (provisional entity)</li>- +<li><p>adult T-cell leukaemia/lymphoma</p></li>
- +<li><p>extranodal NK-/T-cell lymphoma, nasal type</p></li>
- +<li>
- +<p>intestinal T-cell lymphoma</p>
- +<ul>
- +<li><p>enteropathy-associated T-cell lymphoma</p></li>
- +<li><p>monomorphic epitheliotropic intestinal T-cell lymphoma</p></li>
- +<li><p>intestinal T-cell lymphoma, not otherwise specified</p></li>
- +<li><p>indolent T-cell lymphoproliferative disorder of the gastrointestinal tract (provisional entity)</p></li>
-<li>hepatosplenic T-cell lymphoma</li>-<li>subcutaneous panniculitis-like T-cell lymphoma</li>-<li><a title="Mycosis fungoides" href="/articles/mycosis-fungoides">mycosis fungoides</a></li>-<li><a href="/articles/sezary-syndrome">Sézary syndrome</a></li>-<li>primary cutaneous CD30+ T-cell lymphoproliferative disorders<ul>-<li>lymphomatoid papulosis</li>-<li>primary cutaneous anaplastic large cell lymphoma</li>- +<li><p>hepatosplenic T-cell lymphoma</p></li>
- +<li><p>subcutaneous panniculitis-like T-cell lymphoma</p></li>
- +<li><p><a href="/articles/mycosis-fungoides" title="Mycosis fungoides">mycosis fungoides</a></p></li>
- +<li><p><a href="/articles/sezary-syndrome-1">Sézary syndrome</a></p></li>
- +<li>
- +<p>primary cutaneous CD30+ T-cell lymphoproliferative disorders</p>
- +<ul>
- +<li><p>lymphomatoid papulosis</p></li>
- +<li><p>primary cutaneous anaplastic large cell lymphoma</p></li>
-<li>primary cutanoue peripheral T-cell lymphomas, rare subtypes<ul>-<li>primary cutaneous γδ T-cell lymphoma</li>-<li>primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (provisional entity)</li>-<li>primary cutaneous acral CD8+ T-cell lymphoma (provisional entity)</li>-<li>primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (provisional entity)</li>- +<li>
- +<p>primary cutanoue peripheral T-cell lymphomas, rare subtypes</p>
- +<ul>
- +<li><p>primary cutaneous γδ T-cell lymphoma</p></li>
- +<li><p>primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (provisional entity)</p></li>
- +<li><p>primary cutaneous acral CD8+ T-cell lymphoma (provisional entity)</p></li>
- +<li><p>primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (provisional entity)</p></li>
- +<li><p><a href="/articles/peripheral-t-cell-lymphoma">peripheral T-cell lymphoma</a>, not otherwise specified</p></li>
-<a href="/articles/peripheral-t-cell-lymphoma">peripheral T-cell lymphoma</a>, not otherwise specified</li>-<li>angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin<ul>-<li><a href="/articles/angioimmunoblastic-t-cell-lymphoma">angioimmunoblastic T-cell lymphoma</a></li>-<li>follicular T-cell lymphoma (provisional entity)</li>-<li>nodal peripheral T-cell lymphoma with T follicular helper<em> </em>phenotype (provisional entity)</li>- +<p>angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin</p>
- +<ul>
- +<li><p><a href="/articles/angioimmunoblastic-t-cell-lymphoma">angioimmunoblastic T-cell lymphoma</a></p></li>
- +<li><p>follicular T-cell lymphoma (provisional entity)</p></li>
- +<li><p>nodal peripheral T-cell lymphoma with T follicular helper<em> </em>phenotype (provisional entity)</p></li>
-<a href="/articles/anaplastic-large-cell-lymphoma">anaplastic large-cell lymphoma</a><ul>-<li><a href="/articles/anaplastic-large-cell-lymphoma-alk-positive">anaplastic large-cell lymphoma, ALK-positive</a></li>-<li><a href="/articles/anaplastic-large-cell-lymphoma-alk-negative">anaplastic large-cell lymphoma, ALK-negative</a></li>- +<p><a href="/articles/anaplastic-large-cell-lymphoma">anaplastic large-cell lymphoma</a></p>
- +<ul>
- +<li><p><a href="/articles/anaplastic-large-cell-lymphoma-alk-positive">anaplastic large-cell lymphoma, ALK-positive</a></p></li>
- +<li><p><a href="/articles/anaplastic-large-cell-lymphoma-alk-negative">anaplastic large-cell lymphoma, ALK-negative</a></p></li>
-<li>-<a href="/articles/breast-implant-associated-anaplastic-large-cell-lymphoma-2">breast implant-associated anaplastic large-cell lymphoma</a> (provisional entity)</li>- +<li><p><a href="/articles/breast-implant-associated-anaplastic-large-cell-lymphoma-2">breast implant-associated anaplastic large-cell lymphoma</a> (provisional entity)</p></li>
-<a href="/articles/hodgkin-lymphoma">Hodgkin lymphoma</a><ul>-<li>nodular lymphocyte predominant Hodgkin lymphoma</li>-<li>classical Hodgkin lymphoma<ul>-<li>nodular sclerosis classical Hodgkin lymphoma</li>-<li>lymphocyte-rich classical Hodgkin lymphoma</li>-<li>mixed cellularity classical Hodgkin lymphoma</li>-<li>lymphocyte-depleted classical Hodgkin lymphoma</li>- +<p><a href="/articles/hodgkin-lymphoma">Hodgkin lymphoma</a></p>
- +<ul>
- +<li><p>nodular lymphocyte predominant Hodgkin lymphoma</p></li>
- +<li>
- +<p>classical Hodgkin lymphoma</p>
- +<ul>
- +<li><p>nodular sclerosis classical Hodgkin lymphoma</p></li>
- +<li><p>lymphocyte-rich classical Hodgkin lymphoma</p></li>
- +<li><p>mixed cellularity classical Hodgkin lymphoma</p></li>
- +<li><p>lymphocyte-depleted classical Hodgkin lymphoma</p></li>
-<a href="/articles/posttransplant-lymphoproliferative-disorder">posttransplant lymphoproliferative disorders</a> (PTLD)<ul>-<li>plasmacytic hyperplasia PTLD</li>-<li>infectious mononucleosis PTLD</li>-<li>florid follicular hyperplasia PTLD</li>-<li>polymorphic PTLD</li>-<li>monomorphic PTLD<ul>-<li>monomorphic B-cell PTLD</li>-<li>monomorphic T/NK-cell PTLD</li>- +<p><a href="/articles/posttransplant-lymphoproliferative-disorder">posttransplant lymphoproliferative disorders</a> (PTLD)</p>
- +<ul>
- +<li><p>plasmacytic hyperplasia PTLD</p></li>
- +<li><p>infectious mononucleosis PTLD</p></li>
- +<li><p>florid follicular hyperplasia PTLD</p></li>
- +<li><p>polymorphic PTLD</p></li>
- +<li>
- +<p>monomorphic PTLD</p>
- +<ul>
- +<li><p>monomorphic B-cell PTLD</p></li>
- +<li><p>monomorphic T/NK-cell PTLD</p></li>
-<li>classical Hodgkin lymphoma PTLD</li>- +<li><p>classical Hodgkin lymphoma PTLD</p></li>
-<li><a href="/articles/histiocytic-sarcoma">histiocytic sarcoma</a></li>-<li>tumours derived from Langerhans cells<ul>-<li><a href="/articles/langerhans-cell-histiocytosis">Langerhans cell histiocytosis</a></li>-<li><a href="/articles/langerhans-cell-sarcoma">Langerhans cell sarcoma</a></li>- +<li><p><a href="/articles/histiocytic-sarcoma">histiocytic sarcoma</a></p></li>
- +<li>
- +<p>tumours derived from Langerhans cells</p>
- +<ul>
- +<li><p><a href="/articles/langerhans-cell-histiocytosis">Langerhans cell histiocytosis</a></p></li>
- +<li><p><a href="/articles/langerhans-cell-sarcoma">Langerhans cell sarcoma</a></p></li>
-<li>indeterminate dendritic cell tumour</li>-<li>interdigitating dendritic cell sarcoma</li>-<li>follicular dendritic cell sarcoma<ul><li>inflammatory pseudotumour-like follicular/fibroblastic dendritic cell sarcoma</li></ul>-</li>-<li>fibroblastic reticular cell tumour</li>-<li>disseminated juvenile xanthogranuloma</li>-<li><a href="/articles/erdheim-chester-disease">Erdheim-Chester disease</a></li>- +<li><p>indeterminate dendritic cell tumour</p></li>
- +<li><p>interdigitating dendritic cell sarcoma</p></li>
- +<li>
- +<p>follicular dendritic cell sarcoma</p>
- +<ul><li><p>inflammatory pseudotumour-like follicular/fibroblastic dendritic cell sarcoma</p></li></ul>
- +</li>
- +<li><p>fibroblastic reticular cell tumour</p></li>
- +<li><p>disseminated juvenile xanthogranuloma</p></li>
- +<li><p><a href="/articles/erdheim-chester-disease">Erdheim-Chester disease</a></p></li>
-<li><a href="/articles/lymphoma">lymphoma (general)</a></li>-<li><a href="/articles/histiocyte-society-classification-of-histiocytoses">Histiocyte Society classification of histiocytoses</a></li>-<li><a href="/articles/erdheim-chester-disease">non-Langerhans cell histiocytosis </a></li>- +<li><p><a href="/articles/lymphoma">lymphoma (general)</a></p></li>
- +<li><p><a href="/articles/histiocyte-society-classification-of-histiocytoses">Histiocyte Society classification of histiocytoses</a></p></li>
- +<li><p><a href="/articles/erdheim-chester-disease">non-Langerhans cell histiocytosis</a></p></li>
Unable to process the form. Check for errors and try again.